SCH 39166 hydrobromide

Pricing Availability   Qty
说明: High affinity D1-like antagonist
别名: Ecopipam hydrobromide
化学名: (6aS-trans)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide
纯度: ≥99% (HPLC)
说明书
引用文献 (6)
评论
文献 (4)

生物活性 for SCH 39166 hydrobromide

SCH 39166 hydrobromide is a high affinity dopamine D1/D5 receptor antagonist; displays Ki values of 1.2, 2, 980, 5520, 80 and 731 nM for binding to D1, D5, D2, D4, 5-HT and α2a receptors, respectively.

化合物库 for SCH 39166 hydrobromide

SCH 39166 hydrobromide is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for SCH 39166 hydrobromide

分子量 394.73
公式 C19H20ClNO.HBr
储存 Desiccate at RT
纯度 ≥99% (HPLC)
CAS Number 1227675-51-5
PubChem ID 16759171
InChI Key GAUWIDFICGEZKR-JUOYHRLASA-N
Smiles Br.CN1CCC2=C(C=C(O)C(Cl)=C2)[C@@H]2[C@@H]1CCC1=CC=CC=C21

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for SCH 39166 hydrobromide

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 39.47 100

制备储备液 for SCH 39166 hydrobromide

以下数据基于产品分子量 394.73。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2.53 mL 12.67 mL 25.33 mL
5 mM 0.51 mL 2.53 mL 5.07 mL
10 mM 0.25 mL 1.27 mL 2.53 mL
50 mM 0.05 mL 0.25 mL 0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for SCH 39166 hydrobromide

分析证书/产品说明书
选择另一批次:

参考文献 for SCH 39166 hydrobromide

参考文献是支持产品生物活性的出版物。

Wu et al (2005) DA D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J.Med.Chem. 48 680 PMID: 15689153

Terry and Katz (1994) A comparison of the effects of the D1 receptor antagonists SCH 23390 and SCH 39166 on suppression of feeding behaviour by the D1 agonist SKF38393. Psychopharmacology 113 328 PMID: 7862841

McQuade et al (1991) In vivo binding of SCH 39166: a D-1 selective antagonist. J.Pharmacol.Exp.Ther. 257 42 PMID: 1826927


If you know of a relevant reference for SCH 39166 hydrobromide, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 D1 and D5 Receptor Antagonists

关键词: SCH 39166 hydrobromide, SCH 39166 hydrobromide supplier, High, affinity, D1/D5, receptor, antagonists, Dopamine, Receptors, dopaminergic, SCH39166, hydrobromide, Ecopipam, D1, and, D5, 2299, Tocris Bioscience

6 篇 SCH 39166 hydrobromide 的引用文献

引用文献是使用了 Tocris 产品的出版物。 SCH 39166 hydrobromide 的部分引用包括:

Nunes et al (2010) Differential effects of selective adenosine antagonists on the effort-related impairments induced by DA D1 and D2 antagonism. Neuroscience 170 268 PMID: 20600675

Fleischmann et al (2014) RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. Mol Cancer 13 27 PMID: 24517546

Lim et al (2014) A leptin-mediated central mechanism in analgesia-enhanced opioid reward in rats. J Neurosci 34 9779 PMID: 25031415

Sink et al (2008) Cannabinoid CB1 antagonists and DA antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology (Berl) 196 565 PMID: 18004546

Mizuta et al (2013) The DA D1 receptor is expressed and facilitates relaxation in airway smooth muscle. Am J Physiol Regul Integr Comp Physiol 14 89 PMID: 24004608

Zheng et al (2014) Attenuated DArgic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes. Nat Commun 306 R138 PMID: 24305061


您是否知道使用了 Tocris SCH 39166 hydrobromide 的优秀论文? 请告知我们.

SCH 39166 hydrobromide 的评论

目前没有该产品的评论。 Be the first to review SCH 39166 hydrobromide and earn rewards!

Have you used SCH 39166 hydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.